Paragon 28 Adds to Suite of Novel Syndesmosis Repair Solutions with Launch of Grappler® R3INFORCE™ Extraosseous Repair System
28 Marzo 2024 - 9:05PM
Business Wire
Paragon 28, Inc. (NYSE: FNA), is pleased to announce the launch
of the Grappler® R3INFORCE™ Extraosseous Repair System designed to
restore stability to the anterior and posterior ligaments
surrounding the ankle during fibula fracture repairs and high ankle
sprains.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240328312304/en/
Figure 1: Anterior inferior tibiofibular
ligament (“AITFL”) Repair Showing the Grappler® R3INFORCE™ Dynamic
Anchor (left) and Grappler® Knotless Anchor (center). Complete
Extraosseous Repair with Grappler® R3INFORCE™ System shown on
right. (Graphic: Business Wire)
Upon determination of syndesmotic instability, the Grappler®
R3INFORCE™ Anchors are placed in plate holes or other anatomic
locations where pre-loaded suture tape can be routed and tensioned
to address the injured ligament or ligaments. The Dynamic Anchor
allows for micromotion in the repair to better replicate the
mechanics of the native tissue.
This system is highly synergistic with Paragon 28’s existing
offerings and can utilize the recently launched Grappler® Knotless
Sutures. This compatibility allows for multiple configurations for
surgeons to cater their syndesmotic repair to their own treatment
philosophies.
The Grappler® R3INFORCE™ Extraosseous Repair System is sterile
packed and includes all instrumentation needed to complete the case
in multiple configurations, reducing waste and intraoperative
complexity.
Paragon 28’s CEO, Albert DaCosta, commented, “With up to 25% of
all ankle fractures as well as unstable high ankle sprains
requiring implants to facilitate soft tissue healing, syndesmotic
stabilization is a major priority for Paragon 28 and an opportunity
for us to improve patients’ recoveries. In launching the Grappler®
R3INFORCE™ System and Dynamic Knotless Anchor, we are adding to our
comprehensive and growing suite of novel solutions designed
specifically to treat injuries to the highly complex
syndesmosis.”
Surgeon Designer Mark Davies, MD, commented, “Congratulations to
the blue sky thinking and creativity of the Paragon 28 team in
manufacturing the Grappler® R3INFORCE™ Extraosseous Repair System.
It offers surgeons a comprehensive, physiological, and anatomical
reconstruction system for ankle syndesmotic injuries.”
The Grappler® R3INFORCE™ Extraosseous Repair System bolsters
Paragon 28’s soft tissue offering, which includes the Paratrooper™
Plantar Plate System, TenoTac™ 2.0 Soft Tissue Fixation System,
Grappler® Interference Screw System, Grappler® Suture Anchor
System, Grappler® Knotless Anchor System, Bridgeline™ Tape, R3ACT®
Stabilization System, R3LEASE™ Stabilization System, and Mister
Tendon™ Harvester. With this comprehensive portfolio, Paragon 28®
provides its customers with a single source to address their foot
and ankle soft tissue needs.
About Paragon 28, Inc.
Based in Englewood, CO., Paragon 28, is a leading medical device
company exclusively focused on the foot and ankle orthopedic market
and is dedicated to improving patient lives. From the onset,
Paragon 28® has provided innovative orthopedic solutions,
procedural approaches and instrumentation that cover a wide range
of foot and ankle ailments including fracture fixation, forefoot,
ankle, progressive collapsing foot deformity (PCFD) or flatfoot,
Charcot foot and orthobiologics. The company designs products with
both the patient and surgeon in mind, with the goal of improving
outcomes, reducing ailment recurrence and complication rates, and
making the procedures simpler, consistent, and reproducible.
Forward Looking Statements
Except for the historical information contained herein, the
matters set forth in this press release are forward-looking
statements within the meaning of the "safe harbor" provisions of
the Private Securities Litigation Reform Act of 1995, including,
but not limited to: Paragon 28’s potential to shape a better future
for foot and ankle patients. You are cautioned not to place undue
reliance on these forward-looking statements. Forward-looking
statements are only predictions based on our current expectations,
estimates, and assumptions, valid only as of the date they are
made, and subject to risks and uncertainties, some of which we are
not currently aware. Forward‐looking statements should not be read
as a guarantee of future performance or results and may not
necessarily be accurate indications of the times at, or by, which
such performance or results will be achieved. These forward‐looking
statements are based on Paragon 28’s current expectations and
inherently involve significant risks and uncertainties. Actual
results and the timing of events could differ materially from those
anticipated in such forward‐looking statements as a result of these
risks and uncertainties. For a further description of the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to Paragon 28’s business in general, see Paragon 28’s
current and future reports filed with the Securities and Exchange
Commission, including its Annual Report on Form 10-K for the fiscal
year ended December 31, 2022 and its Quarterly Reports on Form
10-Q, as updated periodically with its other filings with the SEC.
These forward-looking statements are made as of the date of this
press release, and Paragon 28 assumes no obligation to update the
forward-looking statements, or to update the reasons why actual
results could differ from those projected in the forward-looking
statements, except as required by law.
Disclaimer
Dr. Davies may report consulting and royalty fees from Paragon
28 in connection with the provision of product development services
to Paragon 28.
Nothing in this material is intended to provide specific medical
advice or to take the place of written law or regulations.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240328312304/en/
Investor Contact Matthew Brinckman Senior Vice President,
Strategy and Investor Relations Phone: (720) 912-1332
Grafico Azioni Paragon 28 (NYSE:FNA)
Storico
Da Feb 2025 a Mar 2025
Grafico Azioni Paragon 28 (NYSE:FNA)
Storico
Da Mar 2024 a Mar 2025